AbbVie (ABBV)
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
$263.84
vs last close−0.64 (−0.24%)
Something off on this page? Send us feedback.
Next report
Oct 30, 26
in 38 days
EPS estimate
$3.86
Revenue estimate
$17.31B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Jan '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$2.16$2.46$2.97$1.86$2.71$2.65$3.65Pending
Estimate$2.98$2.38$2.88$1.77$2.65$2.59$3.61$3.86
Surprise−27.5%+3.4%+3.1%+5.1%+2.3%+2.3%+1.1%—
RevenueReportedEstimate
Jan '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$15.10B$13.34B$15.42B$15.78B$16.62B$15.00B$16.99BPending
Estimate$14.83B$12.93B$15.03B$15.59B$16.41B$14.72B$16.80B$17.31B
Surprise+1.8%+3.2%+2.6%+1.2%+1.2%+1.9%+1.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $4.56 | — | — |
| Sep 2028 | $4.71 | — | — |
| Jun 2028 | $4.63 | — | — |
| Mar 2028 | $3.62 | — | — |
| Dec 2027 | $4.45 | — | — |
| Sep 2027 | $4.34 | — | — |
| Jun 2027 | $4.12 | — | — |
| Mar 2027 | $3.32 | — | — |
| Dec 2026 | $3.90 | — | — |
| Oct 2026 | $3.86 | — | — |
| Jul 2026 | $3.61 | $3.65 | +1.1% |
| Apr 2026 | $2.59 | $2.65 | +2.3% |
| Feb 2026 | $2.65 | $2.71 | +2.3% |
| Oct 2025 | $1.77 | $1.86 | +5.1% |
| Jul 2025 | |||
| Apr 2025 | |||
| Jan 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $4.56 | — | — | $20.80B | — | — | — |
| Sep 2028 | $4.71 | — | — | $20.06B | — | — | — |
| Jun 2028 | $4.63 | — | — | $19.92B | — | — | — |
| Mar 2028 | $3.62 | — | — | $18.15B | — | — | — |
| Dec 2027 | $4.45 | — | — | $19.61B | — | — | — |
| Sep 2027 | $4.34 | — | — | $18.68B | — | — | — |
| Jun 2027 | $4.12 | — | — | $18.14B | — | — | — |
| Mar 2027 | $3.32 | — | — | $16.25B | — | — | — |
| Dec 2026 | $3.90 | — | — | $18.31B | — | — | — |
| Oct 30, 2026 | $3.86 | — | — | $17.31B | — | — | — |
| Jul 31, 2026 | $3.61 | $3.65 | +1.1% | $16.80B | $16.99B | +1.1% | −2.5% |
| Apr 29, 2026 | $2.59 | $2.65 | +2.3% | $14.72B | $15.00B | +1.9% | +3.1% |
| Feb 4, 2026 | $2.65 | $2.71 | +2.3% | $16.41B | $16.62B | +1.2% | −3.8% |
| Oct 31, 2025 | $1.77 | $1.86 | +5.1% | $15.59B | $15.78B | +1.2% | −4.5% |
| Jul 31, 2025 | |||||||
| Apr 25, 2025 | |||||||
| Jan 31, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Jul 25, 2024 | |||||||
| Apr 26, 2024 | |||||||
| Feb 2, 2024 | |||||||
| Oct 27, 2023 | |||||||
| Jul 27, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 9, 2023 | |||||||
| Oct 28, 2022 | |||||||
| Jul 29, 2022 | |||||||
| Apr 29, 2022 | |||||||
| Feb 2, 2022 | |||||||
| Oct 29, 2021 | |||||||
| Jul 30, 2021 | |||||||
| Apr 30, 2021 | |||||||
| Feb 3, 2021 | |||||||
| Oct 30, 2020 | |||||||
| Jul 31, 2020 | |||||||
| May 1, 2020 | |||||||
| Feb 7, 2020 | |||||||
| Nov 1, 2019 | |||||||
| Jul 26, 2019 | |||||||
| Apr 25, 2019 | |||||||
| Jan 25, 2019 | |||||||
| Nov 2, 2018 | |||||||
| Jul 27, 2018 | |||||||
| Apr 26, 2018 | |||||||
| Jan 26, 2018 | |||||||
| Oct 27, 2017 | |||||||
| Jul 28, 2017 | |||||||
| Apr 27, 2017 | |||||||
| Jan 27, 2017 | |||||||
| Oct 28, 2016 | |||||||
| Jul 29, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Jan 29, 2016 | |||||||
| Oct 30, 2015 | |||||||
| Jul 24, 2015 |